- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03980873
Cognitive-Behavioral Therapy for Young Adult Lesbian, Gay and Bisexual: Transdiagnostic Minority Stress Approach
Background: LGB people experience a large number of anxiety and mood disorders, and risk behaviors than heterosexual (Marshall et al., 2011). The evidence points to the importance played by the stress of minorities in the development of such problems (Bränstrom, Hatzenbuehler, Pachankis and Link, 2016).
Objective: The present study aims to adapt and analyze the efficacy of the ESTEEM program designed for this population (Burton, Wang and Pachankis, in press) in: 1) the reduction of psychopathological symptoms, abusive alcohol consumption and risky sexual behavior, 2 ) the decrease in the level of stress, anxiety for rejection, internalized homophobia and level of concealment, and finally, 3) the improvement of assertiveness levels. The effect of the variables social support, emotional regulation strategies and rumination will be analyzed.
Method: A quasi-experimental design will be used, where the LGB people (n = 63, 18<) will be assigned to the experimental group (immediate treatment), or to the control group (three-month waitlist). At baseline, 3-month, 6-month and 12-month assessments, participants completed self-reports of mental health and minority stress.
Results: It is expected that after treatment, LGB people mental health will be improved, as well as, minority stress will be reduced.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Guipuzcoa
-
San Sebastián, Guipuzcoa, Spain, 20018
- Universidad del País Vasco
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
INCLUSION CRITERIA:
- being born male and currently identifying as a man; or being born female and currentry identifying as a female
- gay, lesbian or bisexual identity
- minimum age 18
EXCLUSION CRITERIA:
- not currently receiving regular mental health services
- not having and addictive disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
An experimental group.
The psychological treatment includes 10 sessions of cognitive-behavioural treatment ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders
|
ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (Barlow et al., 2010). Is an individually-delivered cognitive behavioral treatment with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation abilities; reducing maladaptive cognitive, affective, and behavioral avoidance patterns; and improving motivation and self-efficacy for enacting behavior change |
No Intervention: Control
Three-month waitlist
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptom Assessment-45 Questionnaire from baseline to 16 months
Time Frame: baseline (week 0), end of treatment (week 10), and during the maintenance phase
|
Is an inventory developed to assess the intensity of symptoms inventoried during the last weeks.
Each of the 45 items that is integrated in the self-report questionnaire is answered in a likert scale from 0 (nothing) to 4 (a lot), depending on the intensity with which the subject has lived in the last weeks the discomfort that each one explores.
It is evaluated and interpreted in function of 10 primary dimensions (somatization, obsession-compulsion, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychotic and diverse symptoms and three global indexes of psychological disorders).
The application does not require more than 15 minutes.
|
baseline (week 0), end of treatment (week 10), and during the maintenance phase
|
Change of Sexual Compulsivity Scale (SCS) from baseline to 16 months
Time Frame: baseline (week 0), end of treatment (week 10), and during the maintenance phase
|
The SCS contains 10 items (e.g., "my desires to have sex have disrupted my daily life"), rated from 1 (not at all like me) to 4 (very much like me).
Item responses are summed to derive an overall score (range 10-40).
The SCS has high reliability and validity across multiple studies (Hook, Hook, Davis, Worthington, & Penberthy, 2010).
A score of 24 or higher is frequently used to distinguish problematic sexual compulsivity (e.g., Grov, Parsons, & Bimbi, 2010; Ventuneac, Rendina, Grov, Mustanski, & Parsons, 2015).
|
baseline (week 0), end of treatment (week 10), and during the maintenance phase
|
Change of Safer Sex Self-Efficacy Questionnaire (SSSE) from baseline to 16 months
Time Frame: baseline (week 0), end of treatment (week 10), and during the maintenance phase
|
The 13-item SSSE assesses self-efficacy for condom use in various situations (e.g., "When you really need affection," "When your partner says he/she does not want to use a condom") in response to the prompt, "How confident are you that you could avoid having anal sex without a condom?" using a scale ranging from 1 (not at all tempted) to 5 (extremely tempted).
The SSSE predicts condomless anal intercourse among men who have sex with men (MSM; Rendina, 2014).
|
baseline (week 0), end of treatment (week 10), and during the maintenance phase
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Measure of Gay-Related Stress (MOGS) from baseline to 16 months
Time Frame: baseline (week 0), end of treatment (week 10), and during the maintenance phase
|
The MOGS contains 56 stressors related to being gay, which participants rated in terms of the negative and positive impact each stressor had if it occurred in the past 12 months along a scale ranging from -3 (extremely negative) to 3 (extremely positive). The negative impact of gay-related stress predicts depressive symptoms over-and-above general life stress (Lewis et al., 2003). |
baseline (week 0), end of treatment (week 10), and during the maintenance phase
|
Change of Gay-related Rejection Sensitivity Scale (GRSS) from baseline to 16 months
Time Frame: baseline (week 0), end of treatment (week 10), and during the maintenance phase
|
The GRSS assesses the degree to which gay and bisexual men would be anxious about being rejected in each of 14 vignettes because of their sexual orientation, from 1 (very unconcerned) to 6 (very concerned), and the degree to which they would expect such rejection from 1 (very unlikely) to 6 (very likely).
Previous uses of this scale have yielded associations with depression, social anxiety, substance use, and sexual compulsivity (Feinstein, Goldfried, & Davila, 2012; Pachan kis et al., 2015).
|
baseline (week 0), end of treatment (week 10), and during the maintenance phase
|
Change of Internalized Homophobia Scale (IHP) from baseline to 16 months
Time Frame: baseline (week 0), end of treatment (week 10), and during the maintenance phase
|
The IHP assesses how troubled gay and bisexual men are about their sexual identities over the past year.
Participants rate nine items using a scale from 1 (never) to 4 (often).
The IHP is associated with general mental and sexual health problems in a sample of adult gay men (Meyer, 1995).
|
baseline (week 0), end of treatment (week 10), and during the maintenance phase
|
Change of Sexual Orientation Concealment Scale (SOCS) from baseline to 16 months
Time Frame: baseline (week 0), end of treatment (week 10), and during the maintenance phase
|
In the SOCS, participants indicate the degree to which they are "out of the closet" to five domains of people: family; gay, lesbian, and bisexual friends; straight friends; co-workers; and health care providers, using a scale from 1 (out to all) to 4 (out to none).
The SOCS has shown significant positive associations with internalized homophobia and negative associations with gay community connectedness (Frost & Meyer, 2009).
|
baseline (week 0), end of treatment (week 10), and during the maintenance phase
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jose I. Pérez-Fernández, Ph. D, University of the Basque Country (UPV/EHU)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PIF18/233
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression, Anxiety
-
University Hospital, Strasbourg, FranceCompletedAnxiety Depression DisorderFrance
-
ViomeRecruitingDepression | Anxiety Disorders | Anxiety | Mental Health Disorder | Anxiety Depression | Anxiety State | Mental Health | Depression, Anxiety | Mental Health IssueUnited States
-
3-C Institute for Social DevelopmentUniversity of Miami; Stony Brook UniversityCompletedDepression | Anxiety | Depression, Anxiety | Depression in AdolescenceUnited States
-
University Hospital, Strasbourg, FranceRecruitingDepression Anxiety DisorderFrance
-
UCLH/UCL Joint Research OfficeMedical Research Council; Camden and Islington NHS Trust; Central and North West...RecruitingAnxiety Disorders | Anxiety | Anxiety Depression | CBT | Anxiety Disorders and Symptoms | Anxiety Generalized | Generalised Anxiety Disorder | Anxiety Disorder; Mixed With Depression (Mild) | Anxiety Disorder GeneralizedUnited Kingdom
-
University of Southern CaliforniaCompletedAnxiety | Depression, Anxiety | Depression Mild | Attention Concentration DifficultyUnited States
-
NeuroGlove LLCRecruitingDepression | Anxiety | Anxiety Depression | Depression, AnxietyUnited States
-
University of Wisconsin, MadisonNot yet recruiting
-
Northern Jiangsu People's HospitalRecruitingDepression, AnxietyChina
-
University of South FloridaNational Institute of Mental Health (NIMH)RecruitingDepression | Anxiety | Depression/AnxietyUnited States
Clinical Trials on ESTEEM (Effective Sikills to Empower Effective Men)
-
Yale UniversityNational Institute of Mental Health (NIMH)CompletedSexual Minority StressUnited States
-
Florida State UniversityThe Center for Applied Research for Men and Community HealthRecruitingHIV Infections | Homosexuality | BisexualityVietnam
-
Icahn School of Medicine at Mount SinaiCompletedBreast CancerUnited States
-
3MCompletedPeripheral Arterial Vascular DiseaseGermany
-
University of California, San FranciscoPatient-Centered Outcomes Research InstituteCompletedUnsafe Sex | Unprotected SexUnited States
-
McGill University Health Centre/Research Institute...Approved for marketingComparing Visual Reality to High-fidelity Mannequin Stimulation
-
Methodist Health SystemCompletedHSV EncephalitisUnited States
-
BayerNovartisCompletedBronchiectasis | Pulmonary Disease, Chronic ObstructiveUnited States
-
Yonsei UniversityCompletedFemale Patients Undergoing ThyroidectomyKorea, Republic of
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingDiabetes Complications | Type 1 Diabetes | Diabetic Kidney Disease | Diabetic Nephropathies | Autoimmune DiabetesUnited States